{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-027210","form_type":"8-K","ticker":"AIM","cik":"0000946644","company_name":"AIM ImmunoTech Inc.","filed_at":"2026-06-04T13:00:38+00:00","discovered_at":"2026-06-04T13:02:00.225949+00:00","generated_at":"2026-06-04T13:02:45.954426+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"confidence":"high","headline":"AIM ImmunoTech highlights Ampligen preclinical data for Ebola preparedness","bullets":["Video discusses Ampligen as prophylactic/early-onset treatment for Bundibugyo Ebola strain with no approved therapies.","Preclinical findings: 100% protective survival with early Ampligen administration in lethal Ebola mouse model.","Ampligen has orphan drug designation from FDA and EMA for Ebola virus disease.","Updated Ebola-focused corporate presentation available on company website.","CEO Thomas Equels noted urgent need for therapeutic in ongoing outbreak."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-027210","json":"https://secwatch.observer/filing/0001493152-26-027210.json","markdown":"https://secwatch.observer/filing/0001493152-26-027210.md","text":"https://secwatch.observer/filing/0001493152-26-027210.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/946644/000149315226027210/0001493152-26-027210-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/946644/000149315226027210/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T13:02:45.954426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}